Randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer (JCOG9206-2)

Randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer (JCOG9206-2) - Randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer (JCOG9206-2)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000067

Enrollment

280

Registered

2005-08-18

Start date

1993-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric neoplasm

Interventions

Surgery (Gastrectomy with D2 or greater lymph node dissection) Surgery + chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Curative operation with D2 or greater lymph node dissection (2) Histologically proven gastric adenocarcinoma (3) Macroscopically serosa-positive (T3-4) (4) No metastases to level 3 - 4 lymph nodes station (N0-2) (5) 75 years or younger (6) Negative peritoneal lavage cytology (7) Adequate organ function WBC >=4000/mm3, Hb >=11.0g/dl, Plt >=100.000/mm3, AST/ALT, T.Bil, BUN, Creatinine <=2.5 x Normal Upper Limit, Creatinine clearance <=70 ml/min (8) Written informed consent

Exclusion criteria

Exclusion criteria: (1) Prior chemotherapy or radiotherapy (2) Synchronous or metachronous malignancy in other organs

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Relapse-free survival, the site of recurrence	—

Countries

Japan

Contacts

Public ContactMitsuru Sasako, MD, PhD

JCOG9206-2 Coordinating Office Gastric Surgery Division, National Cancer Center Hospital

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026